|View printer-friendly version|
|Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation|
This new policy extends coverage to patients with both chronic and recurrent acute sinusitis. This includes patients with documented evidence of sinus disease upon physician examination, via nasal endoscopy, or on a computer tomographic (CT) scan. The overall criteria for coverage closely aligns with the recently developed clinical consensus statement soon to be published by the
“The recent positive coverage decision by Anthem brings total covered lives for BSD in
With the Anthem policy change, approximately 95% of insured patients in
Entellus is a medical technology company focused on delivering superior patient and physician experiences through products designed for less invasive treatments. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, patients with nasal airway obstruction, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus platform of products provides safe, effective and easy-to-use solutions intended to enable treatment of patients in more cost-effective sites of care. Entellus’s product lines including the XprESS™ ENT Dilation System, Latera™ Absorbable Nasal Implant, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the most cost effective and efficient site of care. Entellus is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
All statements contained in this release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of words such as “intend,” “expect,” “anticipate,” “could,” “may,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include the anticipated benefits of Entellus’s balloon sinus dilation products and the momentum of its business. These forward-looking statements are based on the current expectations of Entellus’s management and involve known and unknown risks and uncertainties that may cause Entellus’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, Entellus’s future operating results and financial performance; adequate levels of coverage or reimbursement for procedures using the company’s products; competition; ability to expand, manage and maintain its direct sales organization and market and sell its products in